WallStreetZenWallStreetZen

NASDAQ: BCAB
Bioatla Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their BCAB stock forecasts and price targets.

Forecast return on equity

Is BCAB forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is BCAB forecast to generate an efficient return on assets?

Company
-586.66%
Industry
31.95%
BCAB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BCAB earnings per share forecast

What is BCAB's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$46.92
Avg 2 year Forecast
-$1.19
Avg 3 year Forecast
-$0.92

BCAB revenue forecast

What is BCAB's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%
BCAB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BCAB revenue growth forecast

How is BCAB forecast to perform vs Biotechnology companies and vs the US market?

Company
-100%
Industry
38.62%
Market
13.78%
BCAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BCAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BCAB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BCAB$5.65N/AN/A
HOTH$0.58$5.00+763.56%Strong Buy
BOLT$4.93$7.00+41.99%Buy
RVPH$0.71$53.33+7,390.59%Strong Buy
CALC$0.62$10.00+1,502.56%Buy
View Top Biotech Stocks

Bioatla Stock Forecast FAQ

What is BCAB's earnings growth forecast for 2026-2028?

(NASDAQ: BCAB) Bioatla's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.57%.

Bioatla's earnings in 2026 is -$59,607,000.On average, 3 Wall Street analysts forecast BCAB's earnings for 2026 to be -$77,742,968, with the lowest BCAB earnings forecast at -$74,694,224, and the highest BCAB earnings forecast at -$80,029,526. On average, 3 Wall Street analysts forecast BCAB's earnings for 2027 to be -$1,977,375, with the lowest BCAB earnings forecast at -$1,899,831, and the highest BCAB earnings forecast at -$2,035,534.

In 2028, BCAB is forecast to generate -$1,521,058 in earnings, with the lowest earnings forecast at -$1,461,409 and the highest earnings forecast at -$1,565,795.

If you're new to stock investing, here's how to buy Bioatla stock.

What is BCAB's revenue growth forecast for 2026-2028?

(NASDAQ: BCAB) Bioatla's forecast annual revenue growth rate of -100% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.

Bioatla's revenue in 2026 is $2,000,000.On average, 3 Wall Street analysts forecast BCAB's revenue for 2026 to be $0, with the lowest BCAB revenue forecast at $0, and the highest BCAB revenue forecast at $0. On average, 3 Wall Street analysts forecast BCAB's revenue for 2027 to be $0, with the lowest BCAB revenue forecast at $0, and the highest BCAB revenue forecast at $0.

In 2028, BCAB is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is BCAB's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BCAB) forecast ROA is -586.66%, which is lower than the forecast US Biotechnology industry average of 31.95%.

What is BCAB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BCAB) Bioatla's current Earnings Per Share (EPS) is -$50.00. On average, analysts forecast that BCAB's EPS will be -$46.92 for 2026, with the lowest EPS forecast at -$45.08, and the highest EPS forecast at -$48.30. On average, analysts forecast that BCAB's EPS will be -$1.19 for 2027, with the lowest EPS forecast at -$1.15, and the highest EPS forecast at -$1.23. In 2028, BCAB's EPS is forecast to hit -$0.92 (min: -$0.88, max: -$0.95).

What is BCAB's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BCAB) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.